Patient status
| Characteristic . | Value . |
|---|---|
| Total no. of subjects | 60 |
| Status, no. (%) | |
| Alive | 32 (53.3) |
| Dead | 28 (46.7) |
| Cause of death, no. (%) | |
| PD | 22 (36.7) |
| Lymphocytic leukemia | 2 (3.4) |
| Myelodysplastic syndrome | 1 (1.7) |
| Pneumonia | 1 (1.7) |
| Pneumonitis | 1 (1.7) |
| Unknown (no autopsy) | 1 (1.7) |
| Reason for discontinuation, no. (%) | |
| Progressive disease/recurrence | 25 (41.7) |
| Toxicity | 20 (33.3) |
| Investigator decision | 7 (11.7) |
| Patient request | 4 (6.7) |
| Normal completion | 2 (3.3) |
| Other* | 2 (3.3) |
| Median total of cycles received (range) | 4 (1-21) |
| Characteristic . | Value . |
|---|---|
| Total no. of subjects | 60 |
| Status, no. (%) | |
| Alive | 32 (53.3) |
| Dead | 28 (46.7) |
| Cause of death, no. (%) | |
| PD | 22 (36.7) |
| Lymphocytic leukemia | 2 (3.4) |
| Myelodysplastic syndrome | 1 (1.7) |
| Pneumonia | 1 (1.7) |
| Pneumonitis | 1 (1.7) |
| Unknown (no autopsy) | 1 (1.7) |
| Reason for discontinuation, no. (%) | |
| Progressive disease/recurrence | 25 (41.7) |
| Toxicity | 20 (33.3) |
| Investigator decision | 7 (11.7) |
| Patient request | 4 (6.7) |
| Normal completion | 2 (3.3) |
| Other* | 2 (3.3) |
| Median total of cycles received (range) | 4 (1-21) |
“Other” represents patients discontinued because of error in calculation of PD or protocol deviation (n = 1 each).